Last reviewed · How we verify
DTaP-IPV vero vaccine
DTaP-IPV vero vaccine is a Combination vaccine Biologic drug developed by Statens Serum Institut. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by presenting inactivated antigens.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by presenting inactivated antigens. Used for Primary immunization against diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.
At a glance
| Generic name | DTaP-IPV vero vaccine |
|---|---|
| Sponsor | Statens Serum Institut |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
DTaP-IPV is a combination vaccine containing inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and inactivated poliovirus particles grown on Vero cells. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, conferring protection against these four infectious diseases. The Vero cell-derived poliovirus component represents an alternative manufacturing platform to traditional kidney cell lines.
Approved indications
- Primary immunization against diphtheria, tetanus, pertussis, and poliomyelitis in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Immunogenicity of After Primary Immunization and Booster Immunization of sIPV
- A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants (PHASE4)
- Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® (PHASE2)
- Safety and Immunogenicity of a New Serum-free DTaP-IPVvero Combination Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTaP-IPV vero vaccine CI brief — competitive landscape report
- DTaP-IPV vero vaccine updates RSS · CI watch RSS
- Statens Serum Institut portfolio CI
Frequently asked questions about DTaP-IPV vero vaccine
What is DTaP-IPV vero vaccine?
How does DTaP-IPV vero vaccine work?
What is DTaP-IPV vero vaccine used for?
Who makes DTaP-IPV vero vaccine?
What drug class is DTaP-IPV vero vaccine in?
What development phase is DTaP-IPV vero vaccine in?
What are the side effects of DTaP-IPV vero vaccine?
Related
- Drug class: All Combination vaccine drugs
- Manufacturer: Statens Serum Institut — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Primary immunization against diphtheria, tetanus, pertussis, and poliomyelitis in infants and children
- Compare: DTaP-IPV vero vaccine vs similar drugs
- Pricing: DTaP-IPV vero vaccine cost, discount & access